文献速递骨软组织肉瘤与黑色素瘤

BRAF黑色素瘤的可及生物标志物及可化学干预的机制亚型

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.
PubMed 文献 · Cancer Discov · 2017-04-28

该研究整合多基因组化学与遗传筛选、黑色素瘤基因组反复出现的结构变异及患者结局数据,在BRAFV600黑色素瘤中识别出两种机制亚型:对临床MEK抑制剂最佳应答者(25%)和因原发耐药机制不应答者(9.9%)。亚型归属可通过稳健的五特征遗传生物标志物预测,TBK1/IKBKε抑制剂对耐药黑色素瘤具有选择性毒性。

要点

  • BRAFV600黑色素瘤存在两种机制亚型,决定对MEK抑制剂与TBK1/IKBKε抑制剂的敏感性差异。
  • 五特征遗传生物标志物可预测亚型归属及临床结局。
  • TBK1/IKBKε抑制剂对耐药黑色素瘤具有选择性毒性。

核心结论

  • BRAFV600黑色素瘤存在两种机制亚型,分别对临床MEK抑制剂敏感或对TBK1/IKBKε抑制剂敏感,可通过五特征遗传生物标志物预测。

研究设计与样本

  • 研究整合多基因组化学与遗传筛选、黑色素瘤肿瘤基因组中反复出现的结构变异及患者结局数据。

主要发现

  • 亚型归属决定对临床MEK抑制剂与TBK1/IKBKε抑制剂的敏感性差异。
  • 五特征遗传生物标志物可预测亚型归属,并识别对临床MEK抑制剂最佳应答者队列及当前靶向治疗不应答者中对TBK1/IKBKε抑制剂敏感的疾病队列。
  • 对临床BRAF/MEK抑制剂最佳应答者占25%,因原发耐药机制不应答者占9.9%。
  • TBK1/IKBKε抑制剂对耐药黑色素瘤具有选择性毒性。

关键数值与推荐

  • 对临床BRAF/MEK抑制剂最佳应答者占25%。
  • 因原发耐药机制不应答者占9.9%。
  • 亚型归属可通过稳健的定量五特征遗传生物标志物预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genomic diversity among melanoma tumors limits durable control with conventional and targeted therapies. Nevertheless, pathologic activation of the ERK1/2 pathway is a linchpin tumorigenic mechanism associated with the majority of primary and recurrent disease. Therefore, we sought to identify therapeutic targets that are selectively required for tumorigenicity in the presence of pathologic ERK1/2 signaling. By integration of multigenome chemical and genetic screens, recurrent architectural variants in melanoma tumor genomes, and patient outcome data, we identified two mechanistic subtypes of BRAFV600 melanoma that inform new cancer cell biology and offer new therapeutic opportunities. Subtype membership defines sensitivity to clinical MEK inhibitors versus TBK1/IKBKε inhibitors. Importantly, subtype membership can be predicted using a robust quantitative five-feature genetic biomarker. This biomarker, and the mechanistic relationships linked to it, can identify a cohort of best responders to clinical MEK inhibitors and identify a cohort of TBK1/IKBKε inhibitor-sensitive disease among nonresponders to current targeted therapy.Significance: This study identified two mechanistic subtypes of melanoma: (1) the best responders to clinical BRAF/MEK inhibitors (25%) and (2) nonresponders due to primary resistance mechanisms (9.9%). We identified robust biomarkers that can detect these subtypes in patient samples and predict clinical outcome. TBK1/IKBKε inhibitors were selectively toxic to drug-resistant melanoma. Cancer Discov; 7(8); 832-51. ©2017 AACR.See related commentary by Jenkins and Barbie, p. 799This article is highlighted in the In This Issue feature, p. 783.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Eskiocak B, McMillan EA, Mendiratta S, et al. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov. 2017. PMID: 28455392. doi:10.1158/2159-8290.CD-16-0955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。